Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xencor, Inc. (XNCR)
USD14.87
-0.08 (-0.54%)
US NASDAQ Healthcare Biotechnology
Address
111 West Lemon Avenue 91016
Pasadena, CA, US
Pasadena, CA, US
CEO
Bassil I. Dahiyat
Website
xencor.com
IPO
2013-12-03
CIK 1326732 ISIN US98401F1057
Description
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD14.87
-0.08 (-0.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
816.9K
Beta
0.93
Float Shares
53.85M
Free Float %
73.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54% | +1.19% | +2.98% | +10.07% | -11.12% | -16.46% | +45.84% | -52.19% | -66.27% | +12.29% | +53.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (27 ratings, all time)
Buy
Price Targets & DCF
Current price
14.87
Low
26.00
+74.8%
Consensus
27.50
+84.9%
Median
27.50
+84.9%
High
29.00
+95.0%
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 9 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 7 |
24.29
+63.3%
|
| All Time | 14 |
31.71
+113.2%
|
Quality scores
Altman Z-Score
1.20
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+13.7% ★ Q1'26: -86.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+65.4% ★ Q1'26: -159.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-29.6% Q1'26: -1,511.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-45.8% Q1'26: -1,724.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-20.9% Q1'26: -126.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.1% Q1'26: +2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.00× Q1'26: -0.58× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 11 EPS Ana. |
Dec 2027 10 Rev. Ana. 10 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.52M
est: 47.33M (-79.9%)
|
27.76M
est: 8.50M (+226.5%)
|
87.52M
est: 86.67M (+1.0%)
|
35.71M
est: 27.18M (+31.4%)
|
40.60M
est: 34.88M (+16.4%)
|
156.70M
est: 163.18M (-4.0%)
|
122.69M
est: 110.09M (+11.4%)
|
275.11M
est: 194.55M (+41.4%)
|
164.58M
est: 164.55M (+0.0%)
|
174.62M
est: 133.62M (+30.7%)
|
110.49M
est: 61.23M (+80.4%)
|
125.58M
est: 128.83M (-2.5%)
|
77.44M
24.66M – 119.88M
-39.9% YoY
|
109.08M
36.87M – 157.20M
+40.9% YoY
|
120.61M
34.40M – 218.79M
+10.6% YoY
|
245.62M
70.04M – 445.55M
+103.6% YoY
|
497.63M
141.91M – 902.71M
+102.6% YoY
|
| EBITDA |
-15.53M
est: -17.49M (+11.2%)
|
-16.47M
est: -3.59M (-358.3%)
|
45.86M
est: -36.62M (+225.2%)
|
-40.70M
est: -49.22M (+17.3%)
|
-75.88M
est: -63.07M (-20.3%)
|
18.12M
est: -68.95M (+126.3%)
|
-71.00M
est: -45.54M (-55.9%)
|
90.14M
est: -82.20M (+209.6%)
|
-45.70M
est: -69.53M (+34.3%)
|
-101.96M
est: -50.99M (-100.0%)
|
-186.17M
est: -23.37M (-696.7%)
|
-46.98M
est: -49.16M (+4.4%)
|
-29.55M
-45.75M – -9.41M
+39.9% YoY
|
-41.62M
-59.99M – -14.07M
-40.9% YoY
|
-46.03M
-83.49M – -13.13M
-10.6% YoY
|
-93.73M
-170.02M – -26.73M
-103.6% YoY
|
-189.90M
-344.48M – -54.16M
-102.6% YoY
|
| EBIT |
-16.41M
est: -18.68M (+12.1%)
|
-17.58M
est: -3.92M (-348.1%)
|
46.14M
est: -39.98M (+215.4%)
|
-42.73M
est: -56.07M (+23.8%)
|
-79.37M
est: -75.71M (-4.8%)
|
13.82M
est: -75.27M (+118.4%)
|
-76.80M
est: -78.41M (+2.1%)
|
82.64M
est: -89.74M (+192.1%)
|
-54.50M
est: -75.91M (+28.2%)
|
-113.46M
est: -57.14M (-98.5%)
|
-198.28M
est: -26.19M (-657.2%)
|
-57.49M
est: -55.10M (-4.4%)
|
-33.12M
-51.27M – -10.55M
+39.9% YoY
|
-46.65M
-67.23M – -15.77M
-40.9% YoY
|
-51.58M
-93.57M – -14.71M
-10.6% YoY
|
-105.04M
-190.54M – -29.95M
-103.6% YoY
|
-212.82M
-386.05M – -60.69M
-102.6% YoY
|
| Net Income |
-16.42M
est: -18.64M (+11.9%)
|
-17.59M
est: -62.28M (+71.8%)
|
23.63M
est: 323.02M (-92.7%)
|
-48.93M
est: -50.79M (+3.7%)
|
-70.41M
est: -63.87M (-10.2%)
|
26.88M
est: 899.87M (-97.0%)
|
-69.33M
est: -52.28M (-32.6%)
|
82.63M
est: 1.05B (-92.1%)
|
-55.18M
est: -127.52M (+56.7%)
|
-133.13M
est: -177.37M (+24.9%)
|
-232.62M
est: -274.06M (+15.1%)
|
-91.92M
est: -120.82M (+23.9%)
|
-304.91M
-436.49M – -118.90M
-152.4% YoY
|
-277.50M
-279.45M – 32.38M
+9.0% YoY
|
-275.49M
-338.20M – -114.02M
+0.7% YoY
|
-124.19M
-255.61M – -8.78M
+54.9% YoY
|
-14.95M
-30.78M – -1.06M
+88.0% YoY
|
| SGA |
7.46M
est: 9.21M (-19.0%)
|
11.96M
est: 2.60M (+359.2%)
|
13.11M
est: 34.86M (-62.4%)
|
17.50M
est: 19.00M (-7.9%)
|
22.47M
est: 29.46M (-23.7%)
|
24.29M
est: 89.35M (-72.8%)
|
29.69M
est: 34.61M (-14.2%)
|
38.84M
est: 59.59M (-34.8%)
|
47.49M
est: 50.40M (-5.8%)
|
53.38M
est: 48.00M (+11.2%)
|
61.22M
est: 22.00M (+178.3%)
|
63.64M
est: 46.28M (+37.5%)
|
27.82M
8.86M – 43.07M
-39.9% YoY
|
39.19M
13.25M – 56.47M
+40.9% YoY
|
43.33M
12.36M – 78.60M
+10.6% YoY
|
88.24M
25.16M – 160.06M
+103.6% YoY
|
178.77M
50.98M – 324.30M
+102.6% YoY
|
| EPS |
-0.52
est: -0.89 (+41.6%)
|
-0.45
est: -0.96 (+53.0%)
|
0.57
est: 0.50 (+14.0%)
|
-1.05
est: -1.20 (+12.6%)
|
-1.31
est: -1.49 (+12.2%)
|
0.48
est: 0.41 (+17.9%)
|
-1.11
est: -1.41 (+21.1%)
|
1.42
est: 0.24 (+483.9%)
|
-0.93
est: -1.51 (+38.3%)
|
-2.08
est: -2.90 (+28.2%)
|
-3.58
est: -3.66 (+2.2%)
|
-1.24
est: -1.77 (+29.9%)
|
-3.69
-5.88 – -1.60
-108.6% YoY
|
-2.91
-3.76 – 0.44
+21.1% YoY
|
-3.16
-4.56 – -1.54
-8.6% YoY
|
-1.67
-3.44 – -0.12
+47.1% YoY
|
-0.20
-0.41 – -0.01
+88.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-208.61M
OE per share TTM
-2.79
Owner's Yield
-21.31%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
44.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
41
Total invested
10.26M
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 9.33M | 16.00% | 9.24M | — | 9.33M | — | HC | Delaware | 2022-01-28 | ↗ |
| 2 | John S. Stafford III | 7.84M | 25.00% | 7.84M | — | 7.84M | 10.00 | IN | United States | 2013-12-16 | ↗ |
| 3 | EcoR1 Capital, LLC | 6.72M | 11.00% | — | 6.72M | — | 6.72M | IA, OO | Delaware | 2024-11-14 | ↗ |
| 4 | Oleg Nodelman | 6.72M | 11.00% | — | 6.72M | — | 6.72M | HC, IN | United States | 2024-11-14 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 6.32M | 10.81% | — | 107.9K | 6.16M | 162.6K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 6 | EcoR1 Capital Fund Qualified, L.P. | 6.32M | 11.00% | — | 6.32M | — | 6.32M | PN | Delaware | 2024-11-14 | ↗ |
| 7 | PRIMECAP Management Company 95-3868081 | 6.16M | 13.11% | 4.70M | — | 6.16M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2018-02-27 | ↗ |
| 8 | 52-0556948 | 5.91M | 10.10% | 1.35M | — | 5.91M | — | IA | Maryland | 2022-02-14 | ↗ |
| 9 | John S. Stafford III (“Stafford”) | 5.01M | 8.80% | 5.01M | — | 5.01M | 11.00 | IN | — | 2020-05-01 | ↗ |
| 10 | PRIMECAP Management Company | 4.99M | 8.53% | 4.99M | — | 4.99M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2022-02-10 | ↗ |
| 11 | FMR LLC | 4.69M | 11.63% | 5.1K | — | 4.69M | — | HC | Delaware | 2015-07-10 | ↗ |
| 12 | Ronin Capital, LLC | 4.40M | 7.70% | 4.40M | — | 4.40M | 11.00 | OO | — | 2020-05-01 | ↗ |
| 13 | Peter Kolchinsky | 3.16M | 7.80% | — | 3.16M | — | — | IN | Delaware | 2015-05-14 | ↗ |
| 14 | RA Capital Management, LLC | 3.16M | 7.80% | — | 3.16M | — | — | IA | Delaware | 2015-05-14 | ↗ |
| 15 | STATE STREET CORPORATION | 3.12M | 4.50% | — | 2.94M | — | — | HC | MA | 2024-10-18 | ↗ |
| 16 | Xencor, Inc. | 3.10M | 7.40% | 3.10M | — | 3.10M | — | CO | Delaware | 2024-10-21 | ↗ |
| 17 | Deerfield Management Company, L.P. | 3.09M | 7.64% | — | 3.09M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 18 | Deerfield Mgmt, L.P. | 3.09M | 7.64% | — | 3.09M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 19 | James E. Flynn | 3.09M | 7.64% | — | 3.09M | — | — | IN | United States | 2016-02-16 | ↗ |
| 20 | Jeremy C. Green | 3.08M | 5.50% | — | 3.08M | — | 3.08M | HC, IN | Delaware | 2019-02-14 | ↗ |
| 21 | Redmile Group, LLC | 3.08M | 5.50% | — | 3.08M | — | 3.08M | IA, OO | Delaware | 2019-02-14 | ↗ |
| 22 | RA Capital Healthcare Fund, L.P. | 2.51M | 6.20% | — | 2.51M | — | — | PN | Delaware | 2015-05-14 | ↗ |
| 23 | Deerfield International Master Fund, L.P. | 1.73M | 4.28% | — | 1.73M | — | — | PN | British Virgin Islands | 2016-02-16 | ↗ |
| 24 | John Stafford, Jr. | 1.64M | 5.20% | 1.64M | — | 1.64M | — | IN | United States | 2013-12-16 | ↗ |
| 25 | Adage Capital Advisors, L.L.C. | 1.60M | 5.09% | — | 1.60M | — | — | OO | United States | 2015-02-05 | ↗ |
| 26 | Adage Capital Partners GP, L.L.C. | 1.60M | 5.09% | — | 1.60M | — | — | OO | United States | 2015-02-05 | ↗ |
| 27 | Adage Capital Partners, L.P. | 1.60M | 5.09% | — | 1.60M | — | — | PN | United States | 2015-02-05 | ↗ |
| 28 | Phillip Gross | 1.60M | 5.09% | — | 1.60M | — | — | IN | United States | 2015-02-05 | ↗ |
| 29 | Robert Atchinson | 1.60M | 5.09% | — | 1.60M | — | — | IN | United States | 2015-02-05 | ↗ |
| 30 | Deerfield Partners, L.P. | 1.36M | 3.36% | — | 1.36M | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 31 | 85-4328500 | 1.35M | 2.20% | 1.29M | — | 4.84M | — | IA | Maryland | 2024-02-14 | ↗ |
| 32 | Ronin Trading, LLC | 605.7K | 1.10% | 605.7K | — | 605.7K | 11.00 | OO | — | 2020-05-01 | ↗ |
| 33 | Xencor, Inc.201622502 | 8.2K | 7.60% | 322.4K | — | 322.4K | — | CO | | 2021-01-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
41
-164 vs prev Q
New positions
2
Closed positions
165
Increased
16
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.41M +1.4M (+100.0%) | 21.66B +21.7B (+100.0%) | 1.90% +1.901 pp | 2.94% +2.936 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 200.0K +200.0K (+100.0%) | 3.06B +3.1B (+100.0%) | 0.27% +0.269 pp | 0.00% +0.005 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 11.93M +120.0K (+1.0%) | 182.61M +44.1M (+31.8%) | 16.03% +0.133 pp | 0.00% +0.001 pp | USD20.33 -24.7% | 6 qtrs — |
| 4 | PRIMECAP MANAGEMENT CO/CA/ | 10.22M -456.7K (-4.3%) | 156.44M +31.2M (+24.9%) | 13.73% -0.640 pp | 0.12% +0.023 pp | USD19.43 -21.2% | 49 qtrs — |
| 5 | VANGUARD GROUP INC | 7.17M +61.7K (+0.9%) | 109.70M +26.4M (+31.7%) | 9.63% +0.066 pp | 0.00% +0.000 pp | USD27.02 -43.3% | 48 qtrs — |
| 6 | BVF INC/IL | 7.13M +4.4M (+160.3%) | 109.22M +77.1M (+239.8%) | 9.59% +5.898 pp | 3.68% +2.374 pp | USD17.13 -10.6% | 6 qtrs — |
| 7 | RTW INVESTMENTS, LP | 6.78M +556.4K (+8.9%) | 103.76M +30.8M (+42.2%) | 9.11% +0.733 pp | 1.04% +0.140 pp | USD15.77 -2.9% | 6 qtrs — |
| 8 | STATE STREET CORP | 4.51M +833.4K (+22.7%) | 69.01M +25.9M (+60.1%) | 6.06% +1.111 pp | 0.00% +0.001 pp | USD22.40 -31.7% | 48 qtrs — |
| 9 | ECOR1 CAPITAL, LLC | 3.25M -2.9M (-47.1%) | 49.77M -22.3M (-30.9%) | 4.37% -3.904 pp | 2.26% -1.201 pp | USD32.53 -52.9% | 29 qtrs — |
| 10 | TCG CROSSOVER MANAGEMENT, LLC | 2.45M +— (+0.0%) | 37.54M +8.8M (+30.5%) | 3.30% -0.006 pp | 1.24% -0.173 pp | USD20.14 -24.0% | 6 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.75M +24.1K (+1.4%) | 26.84M +6.6M (+32.3%) | 2.36% +0.028 pp | 0.00% +0.000 pp | USD26.40 -42.0% | 48 qtrs — |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.60M -91.5K (-5.4%) | 24.52M +4.7M (+23.5%) | 2.15% -0.127 pp | 0.00% +0.001 pp | USD25.81 -40.7% | 44 qtrs — |
| 13 | MORGAN STANLEY | 1.51M +607.9K (+67.5%) | 23.10M +12.5M (+118.6%) | 2.03% +0.815 pp | 0.00% +0.001 pp | USD19.88 -23.0% | 49 qtrs — |
| 14 | LEGAL & GENERAL GROUP PLC | 1.31M +35.1K (+2.8%) | 20.03M +5.1M (+34.1%) | 1.76% +0.044 pp | 0.00% +0.001 pp | USD14.35 +6.7% | 43 qtrs — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 1.25M -339.7K (-21.4%) | 19.13M +487.5K (+2.6%) | 1.68% -0.460 pp | 0.00% +0.000 pp | USD26.20 -41.6% | 38 qtrs — |
| 16 | BAKER BROS. ADVISORS LP | 1.10M +— (+0.0%) | 16.87M +3.9M (+30.5%) | 1.48% -0.003 pp | 0.10% +0.005 pp | USD18.11 -15.5% | 13 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 753.3K -264.2K (-26.0%) | 11.53M -402.3K (-3.4%) | 1.01% -0.358 pp | 0.00% +0.000 pp | USD15.48 -1.1% | 48 qtrs — |
| 18 | JOHNSON & JOHNSON | 748.1K +— (+0.0%) | 11.45M +2.7M (+30.5%) | 1.01% -0.002 pp | 2.06% +0.331 pp | USD40.12 -61.8% | 17 qtrs — |
| 19 | JEFFERIES FINANCIAL GROUP INC. | 720.4K +620.4K (+620.4%) | 11.03M +9.9M (+840.3%) | 0.97% +0.834 pp | 0.06% +0.051 pp | USD14.81 +3.4% | 2 qtrs — |
| 20 | LYNX1 CAPITAL MANAGEMENT LP | 705.6K +705.6K (+100.0%) | 10.80M +10.8M (+100.0%) | 0.95% +0.948 pp | 2.19% +2.187 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 700.4K +12.2K (+1.8%) | 10.72M +2.7M (+32.8%) | 0.94% +0.015 pp | 0.00% +0.000 pp | USD24.97 -38.7% | 47 qtrs — |
| 22 | NORTHERN TRUST CORP | 674.7K -37.5K (-5.3%) | 10.33M +2.0M (+23.6%) | 0.91% -0.052 pp | 0.00% +0.000 pp | USD23.51 -34.9% | 48 qtrs — |
| 23 | UBS GROUP AG | 638.0K -537.2K (-45.7%) | 9.77M -4.0M (-29.1%) | 0.86% -0.725 pp | 0.00% -0.001 pp | USD18.66 -18.0% | 45 qtrs — |
| 24 | BANK OF AMERICA CORP /DE/ | 629.4K -124.4K (-16.5%) | 9.64M +793.8K (+9.0%) | 0.85% -0.169 pp | 0.00% +0.000 pp | USD9.71 +57.7% | 47 qtrs — |
| 25 | MILLENNIUM MANAGEMENT LLC | 594.4K -108.1K (-15.4%) | 9.10M +859.6K (+10.4%) | 0.80% -0.147 pp | 0.00% +0.000 pp | USD10.05 +52.3% | 24 qtrs — |
| 26 | PANAGORA ASSET MANAGEMENT INC | 583.8K -37.3K (-6.0%) | 8.94M +1.7M (+22.7%) | 0.78% -0.052 pp | 0.03% +0.002 pp | USD10.64 +43.9% | 13 qtrs — |
| 27 | TWO SIGMA ADVISERS, LP | 506.6K -303.6K (-37.5%) | 7.76M -1.7M (-18.4%) | 0.68% -0.410 pp | 0.02% -0.004 pp | USD16.62 -7.9% | 23 qtrs — |
| 28 | TORONTO DOMINION BANK | 491.0K +441.0K (+882.0%) | 7.52M +6.9M (+1,181.7%) | 0.66% +0.593 pp | 0.01% +0.010 pp | USD14.95 +2.4% | 2 qtrs — |
| 29 | ERSTE ASSET MANAGEMENT GMBH | 480.2K +100.0K (+26.3%) | 7.35M +3.0M (+67.3%) | 0.65% +0.134 pp | 0.06% +0.019 pp | USD25.03 -38.8% | 29 qtrs — |
| 30 | BRAIDWELL LP | 459.2K -787.1K (-63.2%) | 7.03M -7.6M (-51.9%) | 0.62% -1.061 pp | 0.22% -0.209 pp | USD14.42 +6.2% | 6 qtrs — |
| 31 | HUDSON BAY CAPITAL MANAGEMENT LP | 425.0K -35.0K (-7.6%) | 6.51M +1.1M (+20.6%) | 0.57% -0.048 pp | 0.02% +0.004 pp | USD10.50 +45.8% | 19 qtrs — |
| 32 | ACADIAN ASSET MANAGEMENT LLC | 411.7K -120.5K (-22.6%) | 6.30M +61.0K (+1.0%) | 0.55% -0.163 pp | 0.01% -0.001 pp | USD11.06 +38.4% | 3 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 410.7K -15.1K (-3.6%) | 6.29M +1.3M (+25.9%) | 0.55% -0.021 pp | 0.00% +0.000 pp | USD27.60 -44.5% | 48 qtrs — |
| 34 | BARCLAYS PLC | 359.2K +203.7K (+130.9%) | 5.50M +2.4M (+75.8%) | 0.48% +0.273 pp | 0.00% +0.001 pp | USD13.80 +10.9% | 48 qtrs — |
| 35 | PRINCIPAL FINANCIAL GROUP INC | 340.3K -4.1K (-1.2%) | 5.21M +1.2M (+29.0%) | 0.46% -0.006 pp | 0.00% +0.001 pp | USD31.74 -51.8% | 34 qtrs — |
| 36 | CITADEL ADVISORS LLC | 321.8K -159.4K (-33.1%) | 4.93M -717.2K (-12.7%) | 0.43% -0.215 pp | 0.00% 0.000 pp | USD11.56 +32.4% | 28 qtrs — |
| 37 | JPMORGAN CHASE & CO | 304.0K -97.5K (-24.3%) | 4.65M -55.7K (-1.2%) | 0.41% -0.132 pp | 0.00% +0.000 pp | USD15.27 +0.3% | 49 qtrs — |
| 38 | TWO SIGMA INVESTMENTS, LP | 268.7K -360.6K (-57.3%) | 4.11M -3.3M (-44.3%) | 0.36% -0.486 pp | 0.01% -0.005 pp | USD16.37 -6.5% | 16 qtrs — |
| 39 | INVESCO LTD. | 265.8K +14.2K (+5.7%) | 4.07M +1.1M (+37.9%) | 0.36% +0.019 pp | 0.00% +0.000 pp | USD18.13 -15.6% | 40 qtrs — |
| 40 | JACOBS LEVY EQUITY MANAGEMENT, INC | 259.3K +259.3K (+100.0%) | 3.97M +4.0M (+100.0%) | 0.35% +0.349 pp | 0.02% +0.015 pp | USD15.31 +0.0% | 8 qtrs — |
| 41 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 247.2K -31.0K (-11.1%) | 3.79M +521.7K (+16.0%) | 0.33% -0.042 pp | 0.01% +0.001 pp | USD20.74 -26.2% | 26 qtrs — |
| 42 | DEUTSCHE BANK AG\ | 216.6K +171.3K (+378.8%) | 3.32M +2.8M (+524.9%) | 0.29% +0.230 pp | 0.00% +0.001 pp | USD17.32 -11.6% | 49 qtrs — |
| 43 | WOODLINE PARTNERS LP | 193.1K +— (+0.0%) | 2.96M +691.4K (+30.5%) | 0.26% -0.001 pp | 0.01% +0.001 pp | USD20.12 -23.9% | 6 qtrs — |
| 44 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 191.5K +84.6K (+79.2%) | 2.93M +1.7M (+133.9%) | 0.26% +0.113 pp | 0.05% +0.025 pp | USD13.31 +15.0% | 2 qtrs — |
| 45 | TREXQUANT INVESTMENT LP | 175.2K +39.0K (+28.7%) | 2.68M +1.1M (+68.0%) | 0.24% +0.052 pp | 0.02% +0.008 pp | USD15.16 +1.0% | 14 qtrs — |
| 46 | AMERICAN CENTURY COMPANIES INC | 174.6K +1.2K (+0.7%) | 2.67M +639.4K (+31.4%) | 0.23% +0.001 pp | 0.00% +0.000 pp | USD18.43 -16.9% | 14 qtrs — |
| 47 | RHUMBLINE ADVISERS | 165.8K -10.1K (-5.7%) | 2.54M +475.6K (+23.1%) | 0.22% -0.014 pp | 0.00% +0.000 pp | USD27.85 -45.0% | 46 qtrs — |
| 48 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 165.8K +— (+0.0%) | 2.54M +593.4K (+30.5%) | 0.22% 0.000 pp | 0.24% +0.022 pp | USD28.77 -46.8% | 45 qtrs — |
| 49 | NANTAHALA CAPITAL MANAGEMENT, LLC | 164.6K -935.4K (-85.0%) | 2.52M -10.4M (-80.5%) | 0.22% -1.260 pp | 0.08% -0.365 pp | USD10.00 +53.1% | 4 qtrs — |
| 50 | DCF ADVISERS, LLC | 154.7K -35.0K (-18.4%) | 2.37M +143.4K (+6.4%) | 0.21% -0.048 pp | 0.64% -0.080 pp | USD26.10 -41.3% | 25 qtrs — |
| 51 | AMERIPRISE FINANCIAL INC | 135.8K -10.9K (-7.4%) | 2.08M +358.6K (+20.8%) | 0.18% -0.015 pp | 0.00% +0.000 pp | USD26.62 -42.5% | 26 qtrs — |
| 52 | NUVEEN, LLC | 134.1K +— (+0.0%) | 2.05M +479.9K (+30.5%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD10.64 +43.9% | 4 qtrs — |
| 53 | SG AMERICAS SECURITIES, LLC | 128.3K +37.8K (+41.8%) | 1.97M +903.0K (+85.0%) | 0.17% +0.051 pp | 0.00% -0.001 pp | USD12.79 +19.7% | 25 qtrs — |
| 54 | ALGERT GLOBAL LLC | 124.4K -236.1K (-65.5%) | 1.91M -2.3M (-54.9%) | 0.17% -0.318 pp | 0.03% -0.041 pp | USD10.31 +48.5% | 3 qtrs — |
| 55 | UBS ASSET MANAGEMENT AMERICAS INC | 119.8K -46.4K (-27.9%) | 1.83M -114.9K (-5.9%) | 0.16% -0.063 pp | 0.00% +0.000 pp | USD27.33 -44.0% | 33 qtrs — |
| 56 | SWISS NATIONAL BANK | 119.6K +4.3K (+3.7%) | 1.83M +478.6K (+35.4%) | 0.16% +0.006 pp | 0.00% +0.000 pp | USD23.64 -35.2% | 41 qtrs — |
| 57 | CITIGROUP INC | 112.3K +88.6K (+374.5%) | 1.72M +1.4M (+519.3%) | 0.15% +0.119 pp | 0.00% +0.001 pp | USD16.21 -5.6% | 47 qtrs — |
| 58 | AQR CAPITAL MANAGEMENT LLC | 112.3K +25.5K (+29.3%) | 1.72M +700.5K (+68.8%) | 0.15% +0.034 pp | 0.00% +0.000 pp | USD10.47 +46.2% | 7 qtrs — |
| 59 | ESSEX LLC | 98.7K -1.2K (-1.2%) | 1.51M +339.1K (+29.0%) | 0.13% -0.002 pp | 0.27% +0.055 pp | USD20.11 -23.9% | 6 qtrs — |
| 60 | RAFFERTY ASSET MANAGEMENT, LLC | 97.7K +27.9K (+39.9%) | 1.50M +676.9K (+82.6%) | 0.13% +0.037 pp | 0.01% +0.003 pp | USD18.47 -17.1% | 28 qtrs — |
| 61 | FMR LLC | 92.9K +19.0K (+25.6%) | 1.42M +554.8K (+64.0%) | 0.12% +0.025 pp | 0.00% +0.000 pp | USD12.05 +27.1% | 49 qtrs — |
| 62 | WINTON GROUP LTD | 88.0K -37.4K (-29.8%) | 1.35M -123.7K (-8.4%) | 0.12% -0.051 pp | 0.05% -0.009 pp | USD15.88 -3.6% | 28 qtrs — |
| 63 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 87.7K +87.7K (+100.0%) | 1.34M +1.3M (+100.0%) | 0.12% +0.118 pp | 0.00% +0.005 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 64 | THRIVENT FINANCIAL FOR LUTHERANS | 82.8K -4.7K (-5.4%) | 1.27M +241.0K (+23.5%) | 0.11% -0.007 pp | 0.00% +0.000 pp | USD25.34 -39.6% | 26 qtrs — |
| 65 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 82.9K -12.2K (-12.8%) | 1.25M +136.9K (+12.3%) | 0.11% -0.017 pp | 0.00% +0.000 pp | USD23.43 -34.7% | 47 qtrs — |
| 66 | WELLS FARGO & COMPANY/MN | 79.7K +24.9K (+45.5%) | 1.22M +577.6K (+90.0%) | 0.11% +0.033 pp | 0.00% +0.000 pp | USD18.32 -16.4% | 48 qtrs — |
| 67 | TD ASSET MANAGEMENT INC | 77.8K -7.9K (-9.3%) | 1.19M +185.5K (+18.4%) | 0.10% -0.011 pp | 0.00% +0.000 pp | USD26.31 -41.8% | 44 qtrs — |
| 68 | ALLIANCEBERNSTEIN L.P. | 72.1K +— (+0.0%) | 1.10M +258.1K (+30.5%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD29.42 -48.0% | 47 qtrs — |
| 69 | INTECH INVESTMENT MANAGEMENT LLC | 70.6K +41.0K (+138.6%) | 1.08M +733.9K (+211.4%) | 0.09% +0.055 pp | 0.01% +0.007 pp | USD15.73 -2.7% | 6 qtrs — |
| 70 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 70.5K +10.9K (+18.3%) | 1.08M +381.0K (+54.5%) | 0.09% +0.015 pp | 0.00% +0.001 pp | USD30.49 -49.8% | 26 qtrs — |
| 71 | PRUDENTIAL FINANCIAL INC | 67.6K -4.5K (-6.2%) | 1.03M +189.5K (+22.4%) | 0.09% -0.006 pp | 0.00% +0.000 pp | USD27.34 -44.0% | 36 qtrs — |
| 72 | NEOS INVESTMENT MANAGEMENT LLC | 61.4K +61.4K (+100.0%) | 939.5K +939.5K (+100.0%) | 0.08% +0.083 pp | 0.01% +0.005 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 73 | TEMA ETFS LLC | 60.5K +60.5K (+100.0%) | 925.6K +925.6K (+100.0%) | 0.08% +0.081 pp | 0.07% +0.072 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 74 | ALPS ADVISORS INC | 58.6K +24.6K (+72.3%) | 897.8K +498.6K (+124.9%) | 0.08% +0.033 pp | 0.01% +0.003 pp | USD21.11 -27.5% | 21 qtrs — |
| 75 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 58.5K -73.0 (-0.1%) | 896.1K +208.7K (+30.4%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD22.76 -32.7% | 48 qtrs — |
| 76 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 57.2K -12.9K (-18.4%) | 875.0K +67.0K (+8.3%) | 0.08% -0.017 pp | 0.00% +0.000 pp | USD28.68 -46.6% | 39 qtrs — |
| 77 | ADAR1 CAPITAL MANAGEMENT, LLC | 56.2K -72.7K (-56.4%) | 859.9K -651.7K (-43.1%) | 0.08% -0.098 pp | 0.06% -0.079 pp | USD14.72 +4.0% | 6 qtrs — |
| 78 | POINT72 ASSET MANAGEMENT, L.P. | 55.3K +55.3K (+100.0%) | 847.2K +847.2K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.001 pp | USD15.31 +0.0% | 13 qtrs — |
| 79 | DEKABANK DEUTSCHE GIROZENTRALE | 31.8K +— (+0.0%) | 775.0K +420.0K (+118.3%) | 0.04% 0.000 pp | 0.00% +0.001 pp | USD40.37 -62.1% | 22 qtrs — |
| 80 | BNP PARIBAS ARBITRAGE, SNC | 48.7K -75.4K (-60.8%) | 745.4K -710.6K (-48.8%) | 0.07% -0.102 pp | 0.00% 0.000 pp | USD10.59 +44.6% | 47 qtrs — |
| 81 | SCHONFELD STRATEGIC ADVISORS LLC | 47.8K +35.1K (+274.9%) | 732.6K +582.9K (+389.4%) | 0.06% +0.047 pp | 0.00% +0.002 pp | USD14.36 +6.6% | 2 qtrs — |
| 82 | RUSSELL INVESTMENTS GROUP, LTD. | 47.2K +35.2K (+293.1%) | 722.5K +581.7K (+413.1%) | 0.06% +0.047 pp | 0.00% +0.001 pp | USD18.06 -15.2% | 29 qtrs — |
| 83 | QUANTINNO CAPITAL MANAGEMENT LP | 47.1K +2.0K (+4.5%) | 721.6K +192.6K (+36.4%) | 0.06% +0.003 pp | 0.00% +0.000 pp | USD9.48 +61.5% | 3 qtrs — |
| 84 | PROFUND ADVISORS LLC | 44.0K +26.4K (+150.0%) | 673.0K +466.8K (+226.3%) | 0.06% +0.035 pp | 0.02% +0.014 pp | USD17.08 -10.4% | 12 qtrs — |
| 85 | FRANKLIN RESOURCES INC | 41.2K -3.5K (-7.7%) | 631.2K +107.1K (+20.4%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD21.14 -27.6% | 8 qtrs — |
| 86 | LINDEN THOMAS ADVISORY SERVICES, LLC | 41.0K -1.8K (-4.2%) | 627.1K +125.4K (+25.0%) | 0.06% -0.003 pp | 0.06% +0.013 pp | USD24.59 -37.7% | 11 qtrs — |
| 87 | METLIFE INVESTMENT MANAGEMENT, LLC | 40.2K +5.1K (+14.6%) | 615.6K +204.0K (+49.6%) | 0.05% +0.007 pp | 0.00% +0.001 pp | USD23.88 -35.9% | 33 qtrs — |
| 88 | CIBC PRIVATE WEALTH GROUP, LLC | 40.0K -12.5K (-23.9%) | 612.7K -3.9K (-0.6%) | 0.05% -0.017 pp | 0.00% +0.000 pp | USD19.94 -23.2% | 34 qtrs — |
| 89 | STATE OF WISCONSIN INVESTMENT BOARD | 38.8K +20.3K (+109.3%) | 594.4K +376.8K (+173.2%) | 0.05% +0.027 pp | 0.00% +0.001 pp | USD17.69 -13.5% | 35 qtrs — |
| 90 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 38.4K +1.8K (+4.9%) | 587.0K +157.8K (+36.8%) | 0.05% +0.002 pp | 0.00% +0.000 pp | USD18.83 -18.7% | 7 qtrs — |
| 91 | RAYMOND JAMES FINANCIAL INC | 38.0K +21.3K (+127.4%) | 582.3K +386.1K (+196.8%) | 0.05% +0.029 pp | 0.00% +0.000 pp | USD18.68 -18.0% | 5 qtrs — |
| 92 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 36.4K +519.0 (+1.4%) | 557.0K +137.0K (+32.6%) | 0.05% +0.001 pp | 0.01% +0.002 pp | USD29.64 -48.3% | 26 qtrs — |
| 93 | TUDOR INVESTMENT CORP ET AL | 34.8K +34.8K (+100.0%) | 532.7K +532.7K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD15.31 +0.0% | 1 qtrs NEW |
| 94 | RENAISSANCE TECHNOLOGIES LLC | 34.2K -156.2K (-82.1%) | 523.0K -1.7M (-76.6%) | 0.05% -0.210 pp | 0.00% -0.002 pp | USD11.41 +34.2% | 4 qtrs — |
| 95 | JUMP FINANCIAL, LLC | 33.2K -142.5K (-81.1%) | 508.3K -1.6M (-75.3%) | 0.04% -0.192 pp | 0.01% -0.018 pp | USD9.73 +57.3% | 10 qtrs — |
| 96 | LOUISIANA STATE EMPLOYEES RETIREMENT SYSTEM | 32.7K -100.0 (-0.3%) | 500.6K +115.9K (+30.1%) | 0.04% 0.000 pp | 0.01% +0.002 pp | USD36.10 -57.6% | 27 qtrs — |
| 97 | XTX TOPCO LTD | 32.0K +32.0K (+100.0%) | 490.1K +490.1K (+100.0%) | 0.04% +0.043 pp | 0.01% +0.013 pp | USD15.31 +0.0% | 7 qtrs — |
| 98 | LOS ANGELES CAPITAL MANAGEMENT LLC | 34.1K -64.6K (-65.5%) | 481.8K -676.4K (-58.4%) | 0.05% -0.087 pp | 0.00% -0.002 pp | USD8.33 +83.8% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 131 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.79% | 455.4K | 0.65% |
| 2 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.67% | 146.4K | 0.20% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 0.60% | 1.27M | 0.50% |
| 4 | Invesco S&P SmallCap Health Care ETF PSCH | 0.51% | 839.7K | 0.29% |
| 5 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.39% | 765.4K | 0.47% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.29% | 102.6K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.28% | 30.83M | 0.35% |
| 8 | Inspire Small/Mid Cap ETF ISMD | 0.20% | 645.8K | 0.53% |
| 9 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.13% | 116.2K | 0.89% |
| 10 | State Street SPDR S&P 600 Small Cap Value ETF SLYV | 0.13% | 6.22M | 0.15% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.25
Bullish
Ratio by volume
3.00
Bullish
Buys
9
Sells
4
Shares acquired
1.13M
Shares disposed
16.2K
Cash buys
—
Cash sales
3.00
Net activity
+1,111,441
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Cornelissen Bart Jan | Officer | S-Sale | D | Common Stock | 3,499 | 12.29 | 43.0K | 75,898 | D | ↗ |
| 2026-03-06 | Eckert Celia | Officer | S-Sale | D | Common Stock | 1,767 | 11.02 | 19.5K | 76,918 | D | ↗ |
| 2026-03-06 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 2,502 | 11.02 | 27.6K | 263,831 | D | ↗ |
| 2026-03-06 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 6,606 | 11.02 | 72.8K | 546,316 | D | ↗ |
| 2026-03-05 | Eckert Celia | Officer | S-Sale | D | Common Stock | 3,244 | 11.25 | 36.5K | 78,685 | D | ↗ |
| 2026-03-05 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 4,118 | 11.25 | 46.3K | 266,333 | D | ↗ |
| 2026-03-05 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 14,870 | 11.25 | 167.2K | 552,922 | D | ↗ |
| 2026-03-05 | Cornelissen Bart Jan | Officer | S-Sale | D | Common Stock | 2,517 | 11.25 | 28.3K | 79,397 | D | ↗ |
| 2026-03-03 | Eckert Celia | Officer | S-Sale | D | Common Stock | 1,492 | 11.90 | 17.7K | 81,929 | D | ↗ |
| 2026-03-03 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 2,663 | 11.90 | 31.7K | 270,451 | D | ↗ |
| 2026-03-03 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 6,758 | 11.90 | 80.4K | 567,792 | D | ↗ |
| 2026-03-02 | Eckert Celia | Officer | A-Award | A | Stock Option (Right to Buy) | 112,080 | 12.30 | 1.38M | 112,080 | D | ↗ |
| 2026-03-02 | Desjarlais John R | Officer | A-Award | A | Stock Option (Right to Buy) | 149,440 | 12.30 | 1.84M | 149,440 | D | ↗ |
| 2026-03-02 | Dahiyat Bassil I | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 583,748 | 12.30 | 7.18M | 583,748 | D | ↗ |
| 2026-03-02 | Cornelissen Bart Jan | Officer | A-Award | A | Common Stock | 19,458 | 0.00 | — | 81,914 | D | ↗ |
| 2026-01-23 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 5,322 | 12.51 | 66.6K | 248,207 | D | ↗ |
| 2025-12-22 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 6,311 | 12.51 | 79.0K | 242,885 | D | ↗ |
| 2025-12-22 | Dahiyat Bassil I | Director / Officer | M-Exempt | A | Common Stock | 10,624 | 12.51 | 132.9K | 477,259 | D | ↗ |
| 2025-12-19 | Desjarlais John R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 73,367 | 12.51 | 917.8K | 11,633 | D | ↗ |
| 2025-12-19 | Dahiyat Bassil I | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 114,377 | 12.51 | 1.43M | 10,624 | D | ↗ |
| 2025-07-31 | Deshaies Raymond Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 110,422 | 8.32 | 918.7K | 110,422 | D | ↗ |
| 2025-06-16 | RANIERI RICHARD J | Director | S-Sale | D | Common Stock | 2,993 | 9.22 | 27.6K | 19,183 | D | ↗ |
| 2025-06-16 | Montgomery Alan Bruce | Director | S-Sale | D | Common Stock | 2,215 | 9.22 | 20.4K | 20,611 | D | ↗ |
| 2025-06-16 | GUSTAFSON KURT A | Director | S-Sale | D | Common Stock | 2,993 | 9.22 | 27.6K | 20,183 | D | ↗ |
| 2025-06-16 | GORMAN KEVIN CHARLES | Director | S-Sale | D | Common Stock | 3,173 | 9.22 | 29.3K | 18,905 | D | ↗ |
| 2025-06-16 | Feigal Ellen | Director | S-Sale | D | Common Stock | 2,993 | 9.22 | 27.6K | 19,183 | D | ↗ |
| 2025-06-12 | SIMPSON TODD E | Director | A-Award | A | Common Stock | 13,686 | 0.00 | — | 13,686 | D | ↗ |
| 2025-06-12 | RANIERI RICHARD J | Director | A-Award | A | Common Stock | 13,686 | 0.00 | — | 22,176 | D | ↗ |
| 2025-06-12 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 27,372 | 9.43 | 258.1K | 27,372 | D | ↗ |
| 2025-06-12 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 27,372 | 9.43 | 258.1K | 27,372 | D | ↗ |
| 2025-06-12 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 27,372 | 9.43 | 258.1K | 27,372 | D | ↗ |
| 2025-06-12 | GORMAN KEVIN CHARLES | Director | A-Award | A | Common Stock | 13,686 | 0.00 | — | 22,078 | D | ↗ |
| 2025-06-12 | Feigal Ellen | Director | A-Award | A | Common Stock | 13,686 | 0.00 | — | 22,176 | D | ↗ |
| 2025-05-02 | Valente Nancy | Officer | S-Sale | D | Common Stock | 4,616 | 11.03 | 50.9K | 49,169 | D | ↗ |
| 2025-04-10 | Cornelissen Bart Jan | Officer | S-Sale | D | Common Stock | 3,750 | 8.06 | 30.2K | 61,348 | D | ↗ |
| 2025-03-13 | SIMPSON TODD E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-10 | Valente Nancy | Officer | S-Sale | D | Common Stock | 2,565 | 13.60 | 34.9K | 53,785 | D | ↗ |
| 2025-03-10 | Eckert Celia | Officer | S-Sale | D | Common Stock | 5,740 | 13.60 | 78.0K | 63,507 | D | ↗ |
| 2025-03-10 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 9,697 | 13.60 | 131.9K | 236,574 | D | ↗ |
| 2025-03-10 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 19,716 | 13.60 | 268.1K | 465,419 | D | ↗ |
| 2025-03-04 | Eckert Celia | Officer | A-Award | A | Stock Option (Right to Buy) | 65,847 | 14.15 | 931.7K | 65,847 | D | ↗ |
| 2025-03-04 | Desjarlais John R | Officer | A-Award | A | Stock Option (Right to Buy) | 89,552 | 14.15 | 1.27M | 89,552 | D | ↗ |
| 2025-03-04 | Dahiyat Bassil I | Director / Officer | A-Award | A | Common Stock | 109,745 | 0.00 | — | 485,135 | D | ↗ |
| 2025-03-04 | Cornelissen Bart Jan | Officer | A-Award | A | Common Stock | 21,949 | 0.00 | — | 65,098 | D | ↗ |
| 2025-02-03 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 3,542 | 15.69 | 55.6K | 216,420 | D | ↗ |
| 2025-02-03 | Dahiyat Bassil I | Director / Officer | M-Exempt | A | Common Stock | 8,808 | 15.69 | 138.2K | 375,390 | D | ↗ |
| 2024-12-04 | Montgomery Alan Bruce | Director | M-Exempt | D | Stock Option (Right to Buy) | 430 | 20.00 | 8.6K | 2,062 | D | ↗ |
| 2024-12-02 | Montgomery Alan Bruce | Director | S-Sale | D | Common Stock | 13,301 | 27.03 | 359.5K | 9,140 | D | ↗ |
| 2024-11-22 | Dahiyat Bassil I | Director / Officer | M-Exempt | A | Common Stock | 13,548 | 15.69 | 212.6K | 366,163 | D | ↗ |
| 2024-11-21 | Dahiyat Bassil I | Director / Officer | M-Exempt | A | Common Stock | 49,278 | 15.69 | 773.2K | 401,893 | D | ↗ |
| 2024-11-13 | Dahiyat Bassil I | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,366 | 15.69 | 52.8K | 71,634 | D | ↗ |
| 2024-11-12 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 12,774 | 15.69 | 200.4K | 212,878 | D | ↗ |
| 2024-11-11 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 68,684 | 15.69 | 1.08M | 268,788 | D | ↗ |
| 2024-09-27 | ROSA-BJORKESON DAGMAR | Director | S-Sale | D | Common Stock | 2,503 | 20.68 | 51.8K | 8,490 | D | ↗ |
| 2024-09-27 | RANIERI RICHARD J | Director | S-Sale | D | Common Stock | 2,503 | 20.68 | 51.8K | 8,490 | D | ↗ |
| 2024-09-27 | Montgomery Alan Bruce | Director | S-Sale | D | Common Stock | 1,853 | 20.68 | 38.3K | 9,140 | D | ↗ |
| 2024-09-27 | GUSTAFSON KURT A | Director | S-Sale | D | Common Stock | 2,503 | 20.68 | 51.8K | 9,490 | D | ↗ |
| 2024-09-27 | GORMAN KEVIN CHARLES | Director | S-Sale | D | Common Stock | 2,654 | 20.68 | 54.9K | 8,392 | D | ↗ |
| 2024-09-27 | Feigal Ellen | Director | S-Sale | D | Common Stock | 2,503 | 20.68 | 51.8K | 8,490 | D | ↗ |
| 2024-07-10 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 7,785 | 10.73 | 83.5K | 200,104 | — | ↗ |
| 2024-07-09 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 42,215 | 10.73 | 453.0K | 228,648 | — | ↗ |
| 2024-06-13 | ROSA-BJORKESON DAGMAR | Director | A-Award | A | Common Stock | 5,986 | 0.00 | — | 10,993 | — | ↗ |
| 2024-06-13 | RANIERI RICHARD J | Director | A-Award | A | Stock Option (Right to Buy) | 11,971 | 21.31 | 255.1K | 11,971 | — | ↗ |
| 2024-06-13 | Montgomery Alan Bruce | Director | A-Award | A | Common Stock | 5,986 | 0.00 | — | 10,993 | — | ↗ |
| 2024-06-13 | Klencke Barbara | Director | A-Award | A | Common Stock | 5,986 | 0.00 | — | 5,986 | — | ↗ |
| 2024-06-13 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 11,971 | 21.31 | 255.1K | 11,971 | — | ↗ |
| 2024-06-13 | GORMAN KEVIN CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 11,971 | 21.31 | 255.1K | 11,971 | — | ↗ |
| 2024-06-13 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 11,971 | 21.31 | 255.1K | 11,971 | — | ↗ |
| 2024-05-02 | Valente Nancy | Officer | S-Sale | D | Common Stock | 4,745 | 23.58 | 111.9K | 55,115 | — | ↗ |
| 2024-04-09 | Cornelissen Bart Jan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-11 | Kuch John J | Officer | S-Sale | D | Common Stock | 849 | 23.50 | 20.0K | 121,070 | — | ↗ |
| 2024-03-11 | Eckert Celia | Officer | S-Sale | D | Common Stock | 850 | 23.50 | 20.0K | 45,465 | — | ↗ |
| 2024-03-11 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 1,280 | 23.50 | 30.1K | 186,433 | — | ↗ |
| 2024-03-11 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 2,741 | 23.50 | 64.4K | 351,894 | — | ↗ |
| 2024-03-06 | GUSTAFSON KURT A | Director | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 10.73 | 161.0K | 0 | — | ↗ |
| 2024-03-05 | Valente Nancy | Officer | A-Award | A | Common Stock | 19,634 | 0.00 | — | 59,860 | — | ↗ |
| 2024-03-05 | Kuch John J | Officer | S-Sale | D | Common Stock | 4,474 | 23.43 | 104.8K | 121,919 | — | ↗ |
| 2024-03-05 | Eckert Celia | Officer | S-Sale | D | Common Stock | 3,892 | 23.43 | 91.2K | 33,226 | — | ↗ |
| 2024-03-05 | Desjarlais John R | Officer | A-Award | A | Stock Options | 124,346 | 22.85 | 2.84M | 124,346 | — | ↗ |
| 2024-03-05 | Dahiyat Bassil I | Director / Officer | A-Award | A | Common Stock | 54,538 | 0.00 | — | 354,635 | — | ↗ |
| 2024-02-14 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 11,943 | 11.05 | 132.0K | 173,618 | — | ↗ |
| 2024-02-13 | GORMAN KEVIN CHARLES | Director | P-Purchase | A | Common Stock | 53 | 19.12 | 1.0K | 5,060 | — | ↗ |
| 2024-02-13 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 68,057 | 11.05 | 752.0K | 215,783 | — | ↗ |
| 2023-12-29 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 45,000 | 20.93 | 941.7K | 312,929 | — | ↗ |
| 2023-09-15 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 40,070 | 20.69 | 829.0K | 40,070 | — | ↗ |
| 2023-06-21 | Dahiyat Bassil I | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 76,012 | 4.25 | 323.1K | 0 | — | ↗ |
| 2023-06-20 | ROSA-BJORKESON DAGMAR | Director | A-Award | A | Common Stock | 5,007 | 0.00 | — | 5,007 | — | ↗ |
| 2023-06-20 | RANIERI RICHARD J | Director | A-Award | A | Stock Options | 10,013 | 26.19 | 262.2K | 10,013 | — | ↗ |
| 2023-06-20 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 10,013 | 26.19 | 262.2K | 10,013 | — | ↗ |
| 2023-06-20 | GUSTAFSON KURT A | Director | A-Award | A | Common Stock | 5,007 | 0.00 | — | 5,007 | — | ↗ |
| 2023-06-20 | GORMAN KEVIN CHARLES | Director | A-Award | A | Common Stock | 5,007 | 0.00 | — | 5,007 | — | ↗ |
| 2023-06-20 | Feigal Ellen | Director | A-Award | A | Common Stock | 5,007 | 0.00 | — | 5,007 | — | ↗ |
| 2023-05-01 | Valente Nancy | Officer | A-Award | A | Stock Options | 235,778 | 27.07 | 6.38M | 235,778 | — | ↗ |
| 2023-03-09 | Yang Allen | Officer | S-Sale | D | Common Stock | 1,094 | 29.88 | 32.7K | 73,364 | — | ↗ |
| 2023-03-09 | Kuch John J | Officer | S-Sale | D | Common Stock | 711 | 29.88 | 21.2K | 126,230 | — | ↗ |
| 2023-03-09 | Eckert Celia | Officer | S-Sale | D | Common Stock | 711 | 29.88 | 21.2K | 36,976 | — | ↗ |
| 2023-03-09 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 1,230 | 29.88 | 36.8K | 147,726 | — | ↗ |
| 2023-03-09 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 2,602 | 29.88 | 77.7K | 249,701 | — | ↗ |
| 2023-03-06 | Yang Allen | Officer | S-Sale | D | Common Stock | 4,069 | 31.42 | 127.8K | 74,458 | — | ↗ |
| 2023-03-06 | Kuch John J | Officer | S-Sale | D | Common Stock | 2,774 | 31.42 | 87.1K | 126,941 | — | ↗ |
| 2023-03-06 | Eckert Celia | Officer | S-Sale | D | Common Stock | 2,462 | 31.42 | 77.3K | 37,687 | — | ↗ |
| 2023-03-06 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 4,195 | 31.42 | 131.8K | 148,956 | — | ↗ |
| 2023-03-06 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 5,831 | 31.42 | 183.2K | 252,303 | — | ↗ |
| 2023-03-03 | Kuch John J | Officer | S-Sale | D | Common Stock | 919 | 31.54 | 29.0K | 129,715 | — | ↗ |
| 2023-03-03 | Eckert Celia | Officer | S-Sale | D | Common Stock | 427 | 31.54 | 13.5K | 40,149 | — | ↗ |
| 2023-03-03 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 1,232 | 31.54 | 38.9K | 153,151 | — | ↗ |
| 2023-03-03 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 2,851 | 31.54 | 89.9K | 258,134 | — | ↗ |
| 2023-03-02 | Yang Allen | Officer | A-Award | A | Common Stock | 15,006 | 0.00 | — | 78,527 | — | ↗ |
| 2023-03-02 | Kuch John J | Officer | A-Award | A | Stock Options | 72,029 | 31.43 | 2.26M | 72,029 | — | ↗ |
| 2023-03-02 | Eckert Celia | Officer | A-Award | A | Stock Options | 63,025 | 31.43 | 1.98M | 63,025 | — | ↗ |
| 2023-03-02 | Desjarlais John R | Officer | A-Award | A | Stock Options | 112,545 | 31.43 | 3.54M | 112,545 | — | ↗ |
| 2023-03-02 | Dahiyat Bassil I | Director / Officer | A-Award | A | Common Stock | 52,521 | 0.00 | — | 260,985 | — | ↗ |
| 2022-12-31 | Kuch John J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-19 | Yang Allen | Officer | S-Sale | D | Common Stock | 3,737 | 27.00 | 100.9K | 63,521 | — | ↗ |
| 2022-09-08 | Valente Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 35,282 | 0.00 | — | 35,282 | — | ↗ |
| 2022-06-23 | ROSA-BJORKESON DAGMAR | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 0.00 | — | 21,412 | — | ↗ |
| 2022-06-23 | RANIERI RICHARD J | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 26.58 | 569.1K | 21,412 | — | ↗ |
| 2022-06-23 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 0.00 | — | 21,412 | — | ↗ |
| 2022-06-23 | Hata Yujiro S | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 0.00 | — | 21,412 | — | ↗ |
| 2022-06-23 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 26.58 | 569.1K | 21,412 | — | ↗ |
| 2022-06-23 | GORMAN KEVIN CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 26.58 | 569.1K | 21,412 | — | ↗ |
| 2022-06-23 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 21,412 | 0.00 | — | 21,412 | — | ↗ |
| 2022-03-09 | Yang Allen | Director | S-Sale | D | Common Stock | 1,200 | 28.94 | 34.7K | 66,529 | — | ↗ |
| 2022-03-09 | Kuch John J | Director | S-Sale | D | Common Stock | 690 | 28.93 | 20.0K | 124,591 | — | ↗ |
| 2022-03-09 | Eckert Celia | Director | S-Sale | D | Common Stock | 789 | 28.91 | 22.8K | 28,976 | — | ↗ |
| 2022-03-09 | Desjarlais John R | Director | S-Sale | D | Common Stock | 1,172 | 29.13 | 34.1K | 135,625 | — | ↗ |
| 2022-03-09 | Dahiyat Bassil I | Director | S-Sale | D | Common Stock | 2,494 | 29.00 | 72.3K | 207,815 | — | ↗ |
| 2022-03-03 | Yang Allen | Director | A-Award | A | Stock Options | 66,348 | 0.00 | — | 66,348 | — | ↗ |
| 2022-03-03 | Kuch John J | Officer | A-Award | A | Stock Options | 46,444 | 30.02 | 1.39M | 46,444 | — | ↗ |
| 2022-03-03 | Eckert Celia | Director | A-Award | A | Stock Options | 39,809 | 0.00 | — | 39,809 | — | ↗ |
| 2022-03-03 | Desjarlais John R | Director | S-Sale | D | Common Stock | 1,240 | 29.86 | 37.0K | 100,969 | — | ↗ |
| 2022-03-03 | Dahiyat Bassil I | Director | A-Award | A | Common Stock | 49,761 | 0.00 | — | 210,309 | — | ↗ |
| 2021-12-31 | Kuch John J | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-17 | Yang Allen | Officer | S-Sale | D | Common Stock | 3,664 | 36.62 | 134.2K | 34,555 | — | ↗ |
| 2021-06-29 | Kuch John J | Officer | M-Exempt | A | Common Stock | 7,236 | 15.69 | 113.5K | 109,386 | — | ↗ |
| 2021-06-24 | ROSA-BJORKESON DAGMAR | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | RANIERI RICHARD J | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | Hata Yujiro S | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | GORMAN KEVIN CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-06-24 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 9,728 | 36.01 | 350.3K | 9,728 | — | ↗ |
| 2021-03-08 | Yang Allen | Officer | A-Award | A | Common Stock | 9,263 | 0.00 | — | 37,658 | — | ↗ |
| 2021-03-08 | Kuch John J | Officer | A-Award | A | Stock Options | 36,124 | 43.00 | 1.55M | 36,124 | — | ↗ |
| 2021-03-08 | Eckert Celia | Officer | A-Award | A | Common Stock | 6,021 | 0.00 | — | 9,517 | — | ↗ |
| 2021-03-08 | Desjarlais John R | Officer | A-Award | A | Stock Options | 62,523 | 43.00 | 2.69M | 62,523 | — | ↗ |
| 2021-03-08 | Dahiyat Bassil I | Director / Officer | A-Award | A | Stock Options | 131,993 | 43.00 | 5.68M | 131,993 | — | ↗ |
| 2021-03-03 | Kuch John J | Officer | S-Sale | D | Common Stock | 805 | 45.09 | 36.3K | 85,415 | — | ↗ |
| 2021-03-03 | Eckert Celia | Officer | S-Sale | D | Common Stock | 444 | 44.94 | 20.0K | 3,496 | — | ↗ |
| 2021-03-03 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 1,165 | 45.03 | 52.5K | 91,788 | — | ↗ |
| 2021-03-03 | Dahiyat Bassil I | Director / Officer | S-Sale | D | Common Stock | 2,850 | 44.88 | 127.9K | 141,064 | — | ↗ |
| 2021-03-01 | Kuch John J | Officer | M-Exempt | A | Common Stock | 15,065 | 11.05 | 166.5K | 101,285 | — | ↗ |
| 2020-12-24 | Kuch John J | Officer | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 86,220 | — | ↗ |
| 2020-12-17 | Yang Allen | Officer | S-Sale | D | Common Stock | 3,777 | 43.85 | 165.6K | 28,395 | — | ↗ |
| 2020-12-11 | Kuch John J | Officer | G-Gift | D | Common Stock | 500 | 0.00 | — | 88,220 | — | ↗ |
| 2020-06-25 | ROSA-BJORKESON DAGMAR | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | RANIERI RICHARD J | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | Hata Yujiro S | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | GORMAN KEVIN CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-25 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 13,953 | 33.42 | 466.3K | 13,953 | — | ↗ |
| 2020-06-15 | Kuch John J | Officer | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 88,602 | — | ↗ |
| 2020-06-12 | Kuch John J | Officer | M-Exempt | D | Stock Options | 10,000 | 11.05 | 110.5K | 25,650 | — | ↗ |
| 2020-04-06 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 44,771 | 31.84 | 1.43M | 1,206,005 | — | ↗ |
| 2020-03-20 | Ronin Capital, LLC | 10% Owner | S-Sale | D | Common Stock | 50,770 | 29.89 | 1.52M | 5,012,430 | — | ↗ |
| 2020-03-19 | Ronin Capital, LLC | 10% Owner | S-Sale | D | Common Stock | 26,800 | 28.23 | 756.6K | 5,063,200 | — | ↗ |
| 2020-03-02 | Kuch John J | Officer | A-Award | A | Stock Option (Right to Buy) | 40,663 | 32.28 | 1.31M | 40,663 | — | ↗ |
| 2020-03-02 | Eckert Celia | Officer | A-Award | A | Stock Option (Right to Buy) | 18,884 | 32.28 | 609.6K | 18,884 | — | ↗ |
| 2020-03-02 | Desjarlais John R | Officer | A-Award | A | Common Stock | 9,085 | 0.00 | — | 92,953 | — | ↗ |
| 2020-03-02 | Dahiyat Bassil I | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 141,628 | 32.28 | 4.57M | 141,628 | — | ↗ |
| 2020-01-08 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 60,876 | 36.68 | 2.23M | 1,250,776 | — | ↗ |
| 2020-01-07 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 6,047 | 35.95 | 217.4K | 1,311,652 | — | ↗ |
| 2020-01-06 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 58,862 | 35.81 | 2.11M | 1,317,699 | — | ↗ |
| 2019-12-26 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 4,119 | 40.04 | 164.9K | 1,376,561 | — | ↗ |
| 2019-12-24 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 43,720 | 39.71 | 1.74M | 1,380,680 | — | ↗ |
| 2019-12-23 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 91,677 | 39.51 | 3.62M | 1,424,400 | — | ↗ |
| 2019-12-20 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 73,423 | 39.39 | 2.89M | 1,516,077 | — | ↗ |
| 2019-12-18 | ROSA-BJORKESON DAGMAR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-16 | Yang Allen | Officer | A-Award | A | Common Stock | 31,900 | 0.00 | — | 31,900 | — | ↗ |
| 2019-12-12 | Kuch John J | Officer | G-Gift | D | Common Stock | 500 | 0.00 | — | 73,645 | — | ↗ |
| 2019-12-11 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 37,951 | 38.68 | 1.47M | 1,589,500 | — | ↗ |
| 2019-12-10 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 252,225 | 40.13 | 10.12M | 1,627,451 | — | ↗ |
| 2019-12-09 | STAFFORD JOHN S III | 10% Owner | S-Sale | D | Common Stock | 120,324 | 41.64 | 5.01M | 1,879,676 | — | ↗ |
| 2019-09-06 | Desjarlais John R | Officer | M-Exempt | A | Common Stock | 27,522 | 4.25 | 117.0K | 83,868 | — | ↗ |
| 2019-09-05 | Eckert Celia | Officer | — | D | Stock Option (Right to Buy) | 91,292 | 35.58 | 3.25M | 0 | — | ↗ |
| 2019-08-21 | Kuch John J | Officer | M-Exempt | A | Common Stock | 20,000 | 11.05 | 221.0K | 113,629 | — | ↗ |
| 2019-08-19 | Desjarlais John R | Officer | S-Sale | D | Common Stock | 35,000 | 40.69 | 1.42M | 56,346 | — | ↗ |
| 2019-06-26 | RANIERI RICHARD J | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-26 | Montgomery Alan Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-26 | Hata Yujiro S | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-26 | GUSTAFSON KURT A | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-26 | GORMAN KEVIN CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-26 | Feigal Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 12,731 | 39.08 | 497.5K | 12,731 | — | ↗ |
| 2019-06-06 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 12,641 | 29.87 | 377.6K | 5,090,000 | — | ↗ |
| 2019-05-02 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 14,611 | 29.87 | 436.4K | 5,077,359 | — | ↗ |
| 2019-03-25 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 3,500 | 29.77 | 104.2K | 5,062,748 | — | ↗ |
| 2019-03-22 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 29.96 | 59.9K | 5,059,248 | — | ↗ |
| 2019-03-18 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 1,100 | 29.90 | 32.9K | 5,057,248 | — | ↗ |
| 2019-03-15 | STAFFORD JOHN S III | 10% Owner | P-Purchase | A | Common Stock | 38,300 | 29.02 | 1.11M | 5,056,148 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-230.0K
Shares Outstanding
73.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 742.8K | — | 1.55M | 2.73M | 490.2K | 8.2K | 5.52M | 77.52% | ↗ |
| 2 | 2025 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 547.9K | — | 422.4K | 701.4K | 301.3K | 9.2K | 1.98M | 56.69% | ↗ |
| 3 | 2025 | Bart Jan Cornelissen Chief Financial Officer | 491.6K | — | 310.6K | 515.7K | 243.3K | 81.2K | 1.64M | 50.31% | ↗ |
| 4 | 2025 | Celia E. Eckert General Counsel | 491.6K | — | 310.6K | 515.7K | 243.3K | 9.2K | 1.57M | 52.61% | ↗ |
| 5 | 2025 | Nancy K. Valente, M.D. Former Chief Development Officer | 249.4K | — | — | — | — | 181.3K | 430.8K | 0.00% | ↗ |
| 6 | 2024 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 721.2K | — | 1.25M | 4.40M | 432.7K | 8.2K | 6.81M | 82.94% | ↗ |
| 7 | 2024 | John J. Kuch Former Chief Financial Officer | 143.6K | — | 322.5K | 3.18M | — | 640.2K | 4.29M | 81.72% | ↗ |
| 8 | 2024 | Bart Jan Cornelissen Chief Financial Officer | 338.2K | — | 910.8K | 2.26M | 156.9K | 61.2K | 3.73M | 85.09% | ↗ |
| 9 | 2024 | Nancy K. Valente, M.D. Chief Development Officer | 556.2K | — | 448.6K | 1.46M | 278.1K | 122.6K | 2.87M | 66.63% | ↗ |
| 10 | 2024 | Nancy K. Valente, M.D. Former Chief Development Officer | 556.2K | — | 448.6K | 1.46M | 278.1K | 122.6K | 2.87M | 66.63% | ↗ |
| 11 | 2024 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 534.5K | — | 473.5K | 1.54M | 267.3K | 9.2K | 2.83M | 71.32% | ↗ |
| 12 | 2024 | Celia E. Eckert General Counsel | 475.0K | — | 299.1K | 974.8K | 213.8K | 9.2K | 1.97M | 64.60% | ↗ |
| 13 | 2023 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 700.2K | — | 1.65M | 5.25M | 357.1K | 8.2K | 7.97M | 86.62% | ↗ |
| 14 | 2023 | Nancy K. Valente, M.D. Chief Development Officer | 360.0K | — | 1.06M | 3.49M | 153.0K | 104.7K | 5.17M | 88.05% | ↗ |
| 15 | 2023 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 518.9K | — | 589.6K | 1.87M | 220.5K | 9.2K | 3.21M | 76.70% | ↗ |
| 16 | 2023 | Allen S. Yang, M.D., Ph.D. Former Chief Medical Officer | 260.0K | — | 471.6K | 1.50M | — | 712.8K | 2.94M | 66.96% | ↗ |
| 17 | 2023 | John J. Kuch Chief Financial Officer | 468.0K | — | 377.3K | 1.20M | 179.0K | 9.2K | 2.23M | 70.62% | ↗ |
| 18 | 2023 | John J. Kuch Former Chief Financial Officer | 468.0K | — | 377.3K | 1.20M | 179.0K | 9.2K | 2.23M | 70.62% | ↗ |
| 19 | 2023 | Celia E. Eckert General Counsel | 457.6K | — | 330.1K | 1.05M | 175.0K | 9.2K | 2.02M | 68.26% | ↗ |
| 20 | 2022 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 670.0K | — | 1.49M | 5.13M | 402.0K | 7.2K | 7.71M | 85.99% | ↗ |
| 21 | 2022 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 485.0K | — | 1.08M | 1.17M | 218.2K | 8.2K | 2.96M | 75.92% | ↗ |
| 22 | 2022 | Allen S. Yang, M.D., Ph.D. Former Chief Medical Officer | 500.0K | — | 995.9K | 1.08M | 225.0K | 8.2K | 2.81M | 73.91% | ↗ |
| 23 | 2022 | Allen S. Yang Chief Medical Officer | 500.0K | — | 995.9K | 1.08M | 225.0K | 8.2K | 2.81M | 73.91% | ↗ |
| 24 | 2022 | John J. Kuch Chief Financial Officer | 450.0K | — | 697.1K | 757.1K | 202.5K | 8.2K | 2.11M | 68.76% | ↗ |
| 25 | 2022 | John J. Kuch Former Chief Financial Officer | 450.0K | — | 697.1K | 757.1K | 202.5K | 8.2K | 2.11M | 68.76% | ↗ |
| 26 | 2022 | Celia E. Eckert General Counsel | 440.0K | — | 597.5K | 648.9K | 198.0K | 8.2K | 1.89M | 65.86% | ↗ |
| 27 | 2021 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 625.0K | — | 946.0K | 3.34M | 450.0K | 8.9K | 5.37M | 79.82% | ↗ |
| 28 | 2021 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 465.0K | — | 448.1K | 1.45M | 251.1K | 8.9K | 2.63M | 72.38% | ↗ |
| 29 | 2021 | Allen S. Yang Chief Medical Officer | 480.0K | — | 398.3K | 1.29M | 259.2K | 8.9K | 2.44M | 69.30% | ↗ |
| 30 | 2021 | Allen S. Yang, M.D., Ph.D. Former Chief Medical Officer | 480.0K | — | 398.3K | 1.29M | 259.2K | 8.9K | 2.44M | 69.30% | ↗ |
| 31 | 2021 | John J. Kuch Chief Financial Officer | 415.0K | — | 258.9K | 839.0K | 224.1K | 8.9K | 1.75M | 62.88% | ↗ |
| 32 | 2021 | Celia E. Eckert General Counsel | 400.0K | — | 258.9K | 839.0K | 192.0K | 8.9K | 1.70M | 64.63% | ↗ |
| 33 | 2020 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 600.0K | — | 762.0K | 2.75M | 363.0K | 8.9K | 4.48M | 78.31% | ↗ |
| 34 | 2020 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 437.0K | — | 293.3K | 939.7K | 192.0K | 8.9K | 1.87M | 65.90% | ↗ |
| 35 | 2020 | John J. Kuch Chief Financial Officer | 400.0K | — | 218.8K | 700.4K | 176.0K | 8.9K | 1.50M | 61.11% | ↗ |
| 36 | 2020 | Celia E. Eckert General Counsel | 386.0K | — | 101.6K | 325.3K | 170.0K | 16.9K | 999.7K | 42.70% | ↗ |
| 37 | 2020 | Allen S. Yang Chief Medical Officer | 465.0K | — | — | — | 205.0K | 8.9K | 678.9K | 0.00% | ↗ |
| 38 | 2019 | Paul Foster, M.D. Former Chief Medical Officer | 373.0K | — | — | 5.34M | — | 638.1K | 6.35M | 84.08% | ↗ |
| 39 | 2019 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 566.5K | — | — | 2.85M | 312.0K | 7.9K | 3.73M | 76.24% | ↗ |
| 40 | 2019 | Allen S. Yang Chief Medical Officer | 19.4K | — | 1.20M | 1.33M | — | 180.0K | 2.73M | 92.70% | ↗ |
| 41 | 2019 | Celia E. Eckert General Counsel | 123.4K | — | — | 1.84M | 49.3K | 11.5K | 2.02M | 90.90% | ↗ |
| 42 | 2019 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 424.4K | — | — | 1.29M | 167.0K | 7.9K | 1.89M | 68.33% | ↗ |
| 43 | 2019 | John J. Kuch Chief Financial Officer | 383.6K | — | — | 1.03M | 154.0K | 7.9K | 1.58M | 65.48% | ↗ |
| 44 | 2018 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 550.0K | 46.3K | — | 3.32M | 453.8K | 3.3K | 4.37M | 75.91% | ↗ |
| 45 | 2018 | Paul Foster, M.D. Chief Medical Officer | 437.1K | — | — | 1.24M | 262.3K | 2.8K | 1.94M | 63.76% | ↗ |
| 46 | 2018 | Paul Foster, M.D. Former Chief Medical Officer | 437.1K | — | — | 1.24M | 262.3K | 2.8K | 1.94M | 63.76% | ↗ |
| 47 | 2018 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 412.0K | 27.8K | — | 1.24M | 247.2K | 2.7K | 1.92M | 64.17% | ↗ |
| 48 | 2018 | John J. Kuch Chief Financial Officer | 368.0K | — | — | 1.27M | 223.4K | 2.5K | 1.86M | 68.13% | ↗ |
| 49 | 2018 | Edgardo Baracchini, Jr., Ph.D. Former Chief Business Officer | 200.3K | — | — | 864.6K | — | 404.3K | 1.47M | 58.85% | ↗ |
| 50 | 2017 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 525.0K | — | — | 4.20M | 271.4K | 992.00 | 5.00M | 84.05% | ↗ |
| 51 | 2017 | Paul Foster, M.D. Former Chief Medical Officer | 424.4K | — | — | 1.43M | 159.6K | 992.00 | 2.01M | 70.95% | ↗ |
| 52 | 2017 | Paul Foster, M.D. Chief Medical Officer | 424.4K | — | — | 1.43M | 159.6K | 992.00 | 2.01M | 70.95% | ↗ |
| 53 | 2017 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 381.1K | — | — | 1.43M | 143.3K | 992.00 | 1.95M | 73.11% | ↗ |
| 54 | 2017 | John J. Kuch Vice President, Finance | 340.0K | — | — | 1.43M | 127.8K | 992.00 | 1.90M | 75.29% | ↗ |
| 55 | 2017 | John J. Kuch Chief Financial Officer | 340.0K | — | — | 1.43M | 127.8K | 992.00 | 1.90M | 75.29% | ↗ |
| 56 | 2017 | Edgardo Baracchini, Jr., Ph.D. Chief Business Officer | 312.8K | — | — | 1.18M | 117.6K | 992.00 | 1.61M | 73.17% | ↗ |
| 57 | 2017 | Edgardo Baracchini, Jr., Ph.D. Former Chief Business Officer | 312.8K | — | — | 1.18M | 117.6K | 992.00 | 1.61M | 73.17% | ↗ |
| 58 | 2016 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 480.0K | 36.7K | — | 2.08M | 244.1K | 809.00 | 2.85M | 73.24% | ↗ |
| 59 | 2016 | Paul Foster, M.D. Chief Medical Officer | 412.0K | 48.6K | — | 666.9K | 140.9K | 809.00 | 1.27M | 52.54% | ↗ |
| 60 | 2016 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 350.0K | 20.8K | — | 708.5K | 120.1K | 809.00 | 1.20M | 59.03% | ↗ |
| 61 | 2016 | Edgar Baracchini, Jr., Ph.D. Chief Business Officer | 308.1K | 18.3K | — | 708.5K | 67.2K | 809.00 | 1.10M | 64.24% | ↗ |
| 62 | 2016 | Edgardo Baracchini, Jr., Ph.D. Chief Business Officer | 308.1K | 18.3K | — | 708.5K | 67.2K | 809.00 | 1.10M | 64.24% | ↗ |
| 63 | 2016 | Edgardo Baracchini, Jr., Ph.D. Former Chief Business Officer | 308.1K | 18.3K | — | 708.5K | 67.2K | 809.00 | 1.10M | 64.24% | ↗ |
| 64 | 2016 | John J. Kuch Vice President, Finance | 309.0K | 18.4K | — | 583.5K | 106.0K | 809.00 | 1.02M | 57.34% | ↗ |
| 65 | 2016 | John J. Kuch Chief Financial Officer | 309.0K | 18.4K | — | 583.5K | 106.0K | 809.00 | 1.02M | 57.34% | ↗ |
| 66 | 2015 | Bassil I. Dahiyat, Ph.D. President and Chief Executive Officer | 410.0K | — | — | 1.58M | 184.5K | 751.00 | 2.18M | 72.64% | ↗ |
| 67 | 2015 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 410.0K | — | — | 1.58M | 184.5K | 751.00 | 2.18M | 72.64% | ↗ |
| 68 | 2015 | Paul Foster, M.D. Chief Medical Officer | 400.0K | — | — | 842.8K | 140.0K | 751.00 | 1.38M | 60.92% | ↗ |
| 69 | 2015 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 312.6K | — | — | 895.5K | 109.4K | 751.00 | 1.32M | 67.93% | ↗ |
| 70 | 2014 | Bassil I. Dahiyat, Ph.D. President and Chief Executive Officer | 400.0K | — | — | 969.8K | 128.0K | 523.00 | 1.50M | 64.73% | ↗ |
| 71 | 2014 | Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | 400.0K | — | — | 969.8K | 128.0K | 523.00 | 1.50M | 64.73% | ↗ |
| 72 | 2014 | Bassil I. Dahiyat, Ph.D. President and Chief Executive Officer | 400.0K | — | — | 969.8K | 128.0K | 523.00 | 1.50M | 64.73% | ↗ |
| 73 | 2014 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 289.3K | — | — | 961.1K | 96.1K | 751.00 | 1.35M | 71.34% | ↗ |
| 74 | 2014 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 289.3K | — | — | 961.1K | 96.1K | 751.00 | 1.35M | 71.34% | ↗ |
| 75 | 2014 | Paul Foster, M.D. Chief Medical Officer | 396.0K | — | — | 671.4K | 116.2K | 751.00 | 1.16M | 58.01% | ↗ |
| 76 | 2014 | Paul Foster, M.D. Chief Medical Officer | 369.0K | — | — | 671.4K | 116.2K | 751.00 | 1.16M | 58.01% | ↗ |
| 77 | 2013 | Bassil I. Dahiyat, Ph.D. President and Chief Executive Officer | 363.7K | — | — | 627.1K | 121.1K | 191.2K | 1.30M | 48.12% | ↗ |
| 78 | 2013 | Edgardo Baracchini, Jr., Ph.D. Chief Business Officer | 290.0K | — | — | 193.7K | 90.6K | 616.00 | 574.9K | 33.69% | ↗ |
| 79 | 2013 | John R. Desjarlais, Ph.D. Chief Scientific Officer | 268.7K | — | — | 176.9K | 87.3K | 616.00 | 533.6K | 33.16% | ↗ |
| 80 | 2013 | Paul Foster, M.D. Chief Medical Officer | 322.5K | — | — | 61.4K | 104.6K | 616.00 | 489.1K | 12.55% | ↗ |
| 81 | 2012 | Bassil I. Dahiyat, Ph.D. President and Chief Executive Officer | 358.8K | — | — | — | 87.9K | 175.00 | 446.8K | 0.00% | ↗ |
| 82 | 2012 | Paul Foster, M.D. Chief Medical Officer | 403.0K | — | — | 10.9K | 32.3K | 73.00 | 446.4K | 2.45% | ↗ |
| 83 | 2012 | Edgardo Baracchini, Jr., Ph.D. Chief Business Officer | 286.1K | — | — | — | 66.9K | 175.00 | 353.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bassil I. Dahiyat | Co-Founder, Chief Executive Officer, President & Director | 1M | — |
| John R. Desjarlais | Executive Vice President of Research & Chief Scientific Officer | 858.5K | — |
| Bart Jan Cornelissen | Senior Vice President & Chief Financial Officer | 816.1K | male |
| Celia E. Eckert | Senior Vice President, General Counsel & Corporate Secretary | 744.2K | female |
| Jennifer Sandoz | Senior VIce President of Human Resources | — | female |
| Kirk Rosemark | Senior Vice President of Regulatory Affairs & Quality Assurance | — | male |
| Mark Osterman | Senior Vice President of Clinical Development (Autoimmune) | — | — |
| Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | — | male |
| Dane Vincent Leone | Executive Vice President & Chief Strategy Officer | — | male |
| Eric Kowack | Senior Vice President of Program Leadership & Alliance Management | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XNCR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
